A phase II trial of TIP (paclitaxel, ifosfamide and cisplatin) given as second-line (post-BEP) salvage chemotherapy for patients with metastatic germ cell cancer: a medical research council trial-Reference-Cited by-同舟云学术

A phase II trial of TIP (paclitaxel, ifosfamide and cisplatin) given as second-line (post-BEP) salvage chemotherapy for patients with metastatic germ cell cancer: a medical research council trial

Published:2005-07 Issue:2 Volume:93 Page:178-184
ISSN:0007-0920
Container-title:British Journal of Cancer
language:en
Short-container-title:Br J Cancer

Author:

Mead G M, ,Cullen M H,Huddart R,Harper P,Rustin G J S,Cook P A,Stenning S P,Mason M

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://www.nature.com/articles/6602682.pdf

Reference33 articles.

1. Baniel J, Foster RS, Gonin R, Messemer JE, Donohue JP, Einhorn LH (1995) Late relapse of testicular cancer. J Clin Oncol 13: 1170–1176

2. Beyer J, Kingreen D, Krause M, Schleicher J, Schwaner I, Schwella N, Huhn D, Siegert W (1997) Long term survival of patients with recurrent or refractory germ cell tumors after high dose chemotherapy. Cancer 79: 161–168

3. Beyer J, Stenning S, Gerl A, Fossa S, Siegert W (2002) High dose versus conventional-dose chemotherapy as first-salvage treatment in patients with non-seminomatous germ-cell tumors: a matched-pair analysis. Ann Oncol 13: 599–605

4. Bhatia S, Abonour R, Porcu P, Seshadri R, Nichols CR, Cornetta K, Einhorn LH (2000) High dose chemotherapy as initial salvage chemotherapy in patients with relapsed testicular cancer. J Clin Oncol 18: 3346–3351

5. Bokemeyer C, Bayer J, Metzner B, Ruther U, Harstrick A, Weissbach L, Kohrmann U, Verbeek W, Schmoll HJ (1996) Phase II study of paclitaxel in patients with relapsed or cisplatin-refractory testicular cancer. Ann Oncol 7: 31–34

Cited by 110 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Paclitaxel, Ifosfamide, and Cisplatin as Initial Salvage Chemotherapy for Germ Cell Tumors: Long-Term Follow-Up and Outcomes for Favorable- and Unfavorable-Risk Disease;Journal of Clinical Oncology;2024-09-10

2. Management of recurrent and persistent malignant ovarian germ cell tumors: a narrative review;International Journal of Gynecologic Cancer;2024-07-11

3. SEOM-GG clinical guidelines for the management of germ-cell testicular cancer (2023);Clinical and Translational Oncology;2024-07-03

4. Testicular cancer in 2023: Current status and recent progress;CA: A Cancer Journal for Clinicians;2023-11-10

5. European Association of Urology Guidelines on Testicular Cancer: 2023 Update;European Urology;2023-09